Research shows that while on immunotherapy, plasma levels of PD-L1 expression can be used in order to monitor clinical responses.

CULVER CITY, Calif — Investigational data showing the promise of NantHealth’s Liquid GPS™ technology in monitoring key biomarkers for lung cancer patients will be presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference taking place between Sept. 23-26 in Toronto.

NantHealth (NASDAQ: NH), is a leading next-generation, evidence-based, personalized healthcare company. The company’s Liquid GPS is a blood-based molecular test that provides oncologists with a powerful tool for noninvasive tumor profiling and quantitative monitoring of treatment response.

The mini-oral presentation, “Blood Based Biomarkers: RNA, KRAS and PD-L1 Strongly Matching with Tissue and Showing Correlation with Clinical Responses In NSCLC Patients” to be delivered on Sept 25, 2018 at IASLC, will include investigational data suggesting agreement between tissue and blood-based testing for lung cancer patients in both DNA and RNA.

The investigational data also suggests a significant association between clinical response and changes in plasma cfRNA levels and showed that while on immunotherapy, plasma levels of PD-L1 expression could be used in order to monitor clinical responses.

Presentation details:

Title: Abstract MA19.06 – Blood Based Biomarkers: RNA, KRAS and PD-L1 Strongly Matching with Tissue and Showing Correlation with Clinical Responses In NSCLC Patients
Location: Room 201 BD
Time: 3:45 p.m. — 3:50 p.m.
Presenter: Aurelio Castrellon

NantHealth scientists and technology also supported additional lung cancer research will also be the subject of posters at IASLC:

Title: IDO and Tim3 Gene Expression is Correlated in NSCLC Patients with Low PDL1 Gene Expression
Location: P3.04 Poster Viewing in Exhibit Hall
Time: 12 p.m. to 1 p.m. Sept. 26, 2018

Title: TMB and Immune Checkpoint Inhibitor Gene Expression are Unrelated in NSCLC Patients
Location: P3.04 Poster Viewing in Exhibit Hall
Time: 12 p.m. to 1 p.m., Sept. 26, 2018

About NantHealth
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s focused portfolio exemplifies its unique systems-based approach to personalized healthcare and integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. For more information please visit www.nanthealth.com.

About GPS Cancer
GPS Cancer™ is a unique, comprehensive test available through NantHealth. GPS Cancer integrates tumor/normal DNA and RNA sequencing, with enhanced expression analysis and bioinformatics of complex biologic pathway systems, including the immune system which provides oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in CLIA-certified and CAP-accredited laboratories. For more information, visit www.nanthealth.com/precision-insights/.